Work

ADVL1514, a phase 1 study of ABI-009 (nab-sirolimus) in pediatric patients with recurrent or refractory solid tumors, including CNS tumors as a single agent and in combination with temozolomide and irinotecan: A Children’s Oncology Group pediatric early-phase clinical trial network study.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.10022

Authors: Stuart Cramer, Elizabeth Ann Gilger, Susan Burlingame, Olga Militano, Xiaowei Liu, Charles G. Minard, Alyssa Terry Reddy, Stephan D. Voss, Stacey L. Berg, Joel M. Reid, Elizabeth Fox, Brenda Weigel

Institutions: Prisma Health, Cincinnati Children's Hospital Medical Center, Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center, New York Medical College, Children's Oncology Group, University of California, San Francisco, Boston Children's Hospital, Mayo Clinic, Children's Hospital of Philadelphia, Masonic Cancer Center

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281928616

Cites:

Cited by: 2

Related to: 10